U.S. manufacturer Moderna on Tuesday said it has started COVID-19 vaccine trials for children aged from 6 months to under 12 years old, with plans to enroll about 6,750 participants.
“We are pleased to begin this Phase 2/3 study of mRNA-1273 in healthy children in the U.S. and Canada,” said CEO Stephane Bancel in a statement.
“This pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.”
U.S. health authorities say that fewer children have been sick with COVID-19 compared to adults, but they can be infected and can spread the virus. Most infected children have mild symptoms or no symptoms at all.
School officials across the U.S. are under pressure to fully reopen as soon as possible, but many say they need portable classrooms or shorter school days to meet social distancing rules.
Moderna said 17.8 million adults in the U.S. have received its vaccine. The Pfizer, Moderna and Johnson & Johnson vaccines have all been authorised for emergency use, and the companies are set to deliver more than enough to cover the entire U.S. adult population by mid-year.
You have reached your limit for free articles this month.
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Personalised recommendations
A select list of articles that match your interests and tastes.
Faster pages
Move smoothly between articles as our pages load instantly.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Briefing
We brief you on the latest and most important developments, three times a day.
Support Quality Journalism.
*Our Digital Subscription plans do not currently include the e-paper, crossword and print.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
